T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-12-27: Form 8-K; Period of report 2017-12-22; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2017-11-07: Form 8-K; Period of report 2017-11-02; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-09-19: Form 8-K; Period of report 2017-09-15; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2017-09-14: Form 8-K; Period of report 2017-09-14; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-12-27 | 8-K | 2017-12-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d496730d8k.htm |
| 2017-11-07 | 8-K | 2017-11-02 | 2.02 Results of Operations and Financial Condition | 2.02 On November 2, 2017, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended September 30, 2017 and held a conference call to discuss those results. | d471946d8k.htm |
| 2017-09-19 | 8-K | 2017-09-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 On September 15, 2017, T2 Biosystems, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Canaccord Genuity Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 4,375,000 shares of the Company’s common stock to the Underwriters (the “Offering”). | d453139d8k.htm |
| 2017-09-14 | 8-K | 2017-09-14 | 8.01 Other Events | 8.01 Attached as Exhibit 99.1 hereto is a corporate presentation of T2 Biosystems, Inc. (“T2”, “T2 Biosystems”, “we”, “us”, “our” or the “Company) for use by the Company from time to time at conferences and during meetings with investors and other interested parties. | d351103d8k.htm |
| 2017-09-11 | 8-K | 2017-09-08 | 8.01 Other Events | 8.01 On August 4, 2017, T2 Biosystems, Inc. (the “Company”) completed a pivotal clinical study of the T2Bacteria® Panel, run on the T2Dx® Instrument, which is a qualitative T2 Magnetic Resonance assay designed for the direct detection of bacterial species in human whole blood specimens from patients with suspected bacteremia. | a17-21555_18k.htm |
| 2017-09-05 | 8-K | 2017-08-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a17-21294_18k.htm |
| 2017-08-08 | 8-K | 2017-08-03 | 2.02 Results of Operations and Financial Condition | 2.02 On August 3, 2017, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended June 30, 2017 and held a conference call to discuss those results. | a17-18988_18k.htm |
| 2017-06-06 | 8-K | 2017-06-02 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 (b) There were a total of 30,594,342 shares of the Company’s common stock, par value $0.001 per share, outstanding and entitled to vote at the Annual Meeting. | a17-14678_18k.htm |
| 2017-05-05 | 8-K | 2017-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2017, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended March 31, 2017 and held a conference call to discuss those results. | a17-12419_18k.htm |
| 2017-05-04 | 8-K | 2017-05-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (c) On April 27, 2017, the Company’s Board of Directors appointed Darlene Deptula-Hicks to serve as the Company’s Chief Financial Officer and Treasurer, effective May 1, 2017. | a17-12317_18k.htm |
| 2017-03-08 | 8-K | 2017-03-02 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 The balance sheet and statements of operations and comprehensive loss for T2 Biosystems’ (the “Company’s”) fiscal quarter and fiscal year ended December 31, 2016 are furnished with this report as Exhibit 99.1. 5.02 (b) On March 2, 2017, Shawn Lynch notified the Company of his resignation from his position as the Company’s Chief Financial Officer effective immediately. | a17-7857_18k.htm |
| 2017-03-03 | 8-K | 2017-03-02 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a17-7549_18k.htm |
| 2017-02-16 | 8-K | 2017-02-13 | 2.02 Results of Operations and Financial Condition | 2.02 On February 13, 2017, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter and fiscal year ended December 31, 2016 and held a conference call to discuss those results. | a17-4519_18k.htm |
| 2017-01-20 | 8-K | 2017-01-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 17, 2017, T2 Biosystems, Inc. (the “Company”) received a written letter of resignation from Joshua Bilenker stating that he resigned, effective immediately, from his position as a Class II director of the Company and all committees of the Board of Directors of the Company (the “Board”) on which he was serving. | a17-2718_18k.htm |
| 2017-01-11 | 8-K | 2017-01-09 | 2.02 Results of Operations and Financial Condition | 2.02 On January 9, 2017 the Company announced certain preliminary results for the quarter ended December 31, 2016. | a17-1802_18k.htm |
| 2017-01-06 | 8-K | 2016-12-30 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 1.02 The information set forth above in Item 1.01 relating to the Prior Agreement and Note is incorporated herein by reference. 2.03 The information set forth in Item 1.01 above with respect to the Loan Agreement is incorporated herein by reference. 3.02 The information set forth in Item 1.01 above with respect to the CRG Warrants is incorporated herein by reference. 7.01 On January 5, 2017, the Company issued a press release regarding the Loan Agreement and certain agreements and transactions related thereto. | a17-1393_18k.htm |